The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Transforming CDMO partnerships through
Quality is the underpinning of success in the pharmaceutical development and manufacturing industry.
A commitment to quality is not only required to meet regulatory guidelines, it’s also foundational to:
- Accelerating time to market
- Reducing unnecessary risk
- Improving return on investment
- Creating effective medicines
- Ultimately saving patient lives
Despite its critical importance, quality is often mischaracterized, whether by conflating it with compliance, describing it as an end-of-the-line activity, or attributing responsibility to a single team.
In fact, quality is difficult to fully classify because it’s not defined by one single activity, role, process, strategy, or outcome. Rather, it’s a combination and culmination of all these factors — plus more.
This whitepaper takes an in-depth look at key indicators of CDMO quality, identifying tools and best practices to drive continuous improvement, strengthen collaboration, and ultimately cultivate trust.
